Trial · NCT06444399
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
NCT06444399, Phase 2, Completed, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris. Trials, record NCT06444399. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06444399
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
- NCT number
- NCT06444399
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Pityriasis Rubra Pilaris
- Interventions
- Deucravacitinib
- First posted
- 2024-06-05
- Last updated
- 2026-08-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Psoriasis Area and Severity Index (PASI) Scores | Baseline, 24 weeks | The Psoriasis Area and Severity Index (PASI) is used to assess the severity of psoriasis. The PASI score evaluates the discoloration, thickness, scaling, and coverage of psoriatic plaques on the skin. It ranges from 0 to 72, with higher scores indicating greater severity. |
| Secondary | Change in Patient´s Assessment of Itch as Measured by Numeric Rating Scale | Baseline, 24 weeks | The Itch Numeric Rating Scale is a self-administered patient-reported outcome instrument used to assess the severity of itching in patients with atopic dermatitis. It asks patients to rate their worst level of itching in the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst itch imaginable), with higher scores indicating a worse itch. |
| Secondary | Change in the Dermatology Life Quality Index (DLQI) | Baseline, 24 weeks | The DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. |
| Secondary | Change in the Skindex-16 | Baseline, 24 weeks | Skindex-16 consists of domain scores that assess how symptoms, emotions, and functioning from the skin issue affect the QOL of patients with skin conditions. The overall score averages the 3 domain scores, all of which are normalized to a 0 to 100 scale, where 0 indicates that their skin condition has no impact on QOL and 100 represents maximal impact on QOL for the worse. |
| Secondary | Number of Subject's Who Were Responsive to Treatment Based on the Physician Global Assessment (PGA) | Baseline; 24 weeks | The Physician Global Assessment (PGA) is a clinician-reported tool used to evaluate a patient's overall disease severity and overall treatment response at a given point in time. The clinician rates a patient's overall disease severity and overall treatment response from +4 (markedly improved) to -4 (markedly worse). A treatment response is defined as a score of +1 or higher. |
| Secondary | Change in Total Body Surface Area (BSA) Affected by Pityriasis Rubra Pilaris | Baseline; Week 24 | Body Surface Area is an investigator-estimated measure of the extent of skin involvement from pityriasis rubra pilaris. The percentage of total body surface area affected was recorded for the head, upper limbs, trunk, and lower limbs and combined to obtain total affected BSA. Change from baseline was calculated as the follow-up value (week 24) minus the baseline value; negative values indicate improvement. |
| Secondary | Change in Regional Body Surface Area (BSA) Affected by Pityriasis Rubra Pilaris (PRP) | Baseline; 24 Weeks | Regional Body Surface Area is an investigator-estimated measure of the extent of skin involvement from pityriasis rubra pilaris (PRP). For each body region, the percentage points of the participant's total body surface area affected by PRP were estimated using the Rule of Nines (head: 0-9%; upper limbs: 0-18%; trunk: 0-36%; lower limbs: 0-36%). Change from baseline was calculated as week 24 value minus the baseline value; negative values indicate improvement. Values represent percentage points of total body surface area affected rather than percent change from a previous assessment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06444399
GET https://conductscience.org/api/trials/v1/NCT06444399/registered